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Identification of epigenetic signature 
associated with alpha thalassemia/mental 
retardation X-linked syndrome
Laila C. Schenkel1, Kristin D. Kernohan2, Arran McBride2, Ditta Reina8,9, Amanda Hodge8,9, 
Peter J. Ainsworth1,3,4,5,6,7, David I. Rodenhiser4,5,6,7, Guillaume Pare8,9, Nathalie G. Bérubé4,5,6,7, Cindy Skinner10, 
Kym M. Boycott2, Charles Schwartz10 and Bekim Sadikovic1,3,7*
Abstract 
Background: Alpha thalassemia/mental retardation X-linked syndrome (ATR-X) is caused by a mutation at the 
chromatin regulator gene ATRX. The mechanisms involved in the ATR-X pathology are not completely understood, but 
may involve epigenetic modifications. ATRX has been linked to the regulation of histone H3 and DNA methylation, 
while mutations in the ATRX gene may lead to the downstream epigenetic and transcriptional effects. Elucidating the 
underlying epigenetic mechanisms altered in ATR-X will provide a better understanding about the pathobiology of 
this disease, as well as provide novel diagnostic biomarkers.
Results: We performed genome-wide DNA methylation assessment of the peripheral blood samples from 18 
patients with ATR-X and compared it to 210 controls. We demonstrated the evidence of a unique and highly spe-
cific DNA methylation “epi-signature” in the peripheral blood of ATRX patients, which was corroborated by targeted 
bisulfite sequencing experiments. Although genomically represented, differentially methylated regions showed 
evidence of preferential clustering in pericentromeric and telometric chromosomal regions, areas where ATRX has 
multiple functions related to maintenance of heterochromatin and genomic integrity.
Conclusion: Most significant methylation changes in the 14 genomic loci provide a unique epigenetic signature 
for this syndrome that may be used as a highly sensitive and specific diagnostic biomarker to support the diagnosis 
of ATR-X, particularly in patients with phenotypic complexity and in patients with ATRX gene sequence variants of 
unknown significance.
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Background
An emerging development in the field of medical genet-
ics has been the identification of Mendelian disorders 
involving genes encoding the writers, erasers, readers 
and remodelers of the epigenetic machinery [1]. Building 
on several decades of evidence regarding the functions 
of covalent DNA methylation [2, 3] and histone modifi-
cations [4] in regulating gene transcription, it is evident 
that mutations in the proteins responsible for creating, 
interpreting or removing the broad arrays of epigenetic 
marks can be linked to genetic conditions including can-
cer [5], imprinting disorders and/or single-gene disorders 
[6].
Along with these discoveries came the opportunity, not 
only for the elucidation of underlying molecular mecha-
nisms altered in these disorders, but also for the identifi-
cation of epi-signatures that can be diagnostically useful, 
specifically where patients express a subset of clinical 
manifestations associated with a phenotypic spectrum 
shared across more than one syndrome, making a specific 
clinical diagnosis difficult to reach.
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Among the rapidly expanding number of proteins 
responsible for chromatin maintenance and remodeling 
related to transcription is alpha thalassemia/mental 
retardation X-linked (ATRX; NG_008838.2). Mutations 
in the ATRX gene cause alpha thalassemia/mental retar-
dation X-linked syndrome (ATR-X, OMIM 301040), a 
disorder characterized by moderate to severe intellectual 
disability, expressive language disorder, characteristic 
facial gestalt during infancy, often associated with hema-
tological signs of alpha thalassemia [7].
The ATRX protein functions as an agent of ATP-
dependent chromatin remodeling and is a member of the 
SWI/SNF superfamily of proteins. The latter can have a 
wide variety of cellular functions, as described in detail 
in several recent reviews [8–10]. Briefly, ATRX protein 
is involved in cellular processes such as meiosis, mitosis, 
DNA repair and regulation of transcription through an 
effect on chromatin [11–15]. Disruption of these activi-
ties may contribute to developmental abnormalities asso-
ciated with the ATR-X syndrome.
Within the ATRX protein, a histone-binding ATRX–
DNMT3–DNMT3L (ADD) domain can sense the meth-
ylation modifications of both H3K4 and H3K9 [16], 
essentially acting as an interpreter of these histone states. 
ATRX is also known to associate with the transcription 
cofactor DAXX. ATRX–DAXX complex is responsible 
for deposition of histone H3.3 at the telomeric and peri-
centromeric heterochromatic regions within chromo-
somes [17]. Loss of ATRX in ES cells leads to the loss of 
histone H3.3 at imprinting control regions and telom-
eric regions, along with the concurrent loss of H3K9me3 
[18, 19]. ATRX has also been linked to DNA methyla-
tion regulation, as mutations at the ATRX gene result in 
DNA methylation changes at subtelomeric and repetitive 
regions [20].
The role of ATRX as a regulator of heterochromatin 
dynamics raises the possibility that mutations in ATRX 
may lead to downstream transcriptional effects across 
the complex of genes or repetitive regions involved in the 
global context of the disorder, in addition to explaining 
phenotypical differences in these patients. For example, 
ATRX mutations affect the expression of α-globin gene 
cluster, causing α-thalassemia [21]. Mechanistically, 
α-globin cluster, among other genes, has G-rich tandem 
repeats (TRs) sites, which have been reported to bind 
ATRX resulting in H3.3 deposition and gene expression 
regulation. In addition, it was suggested that the differ-
ences in size of these TRs among ATR-X patients con-
tribute to the ranges in severity of the syndrome [22].
The orchestrated regulation of epigenetic mechanisms, 
including associations between ATRX and DNA methyla-
tion [11, 12], is essential for tissue homeostasis, cell iden-
tity and proper human development. Here, we describe 
the findings of a genome-wide DNA methylation array 
(GWMA) performed on peripheral blood samples from 
patients with ATR-X and show the genome-wide changes 
in DNA methylation that occur in patients with this epi-
genetic syndrome. We have identified a specific epi-sig-
nature of differentially hypo- and hypermethylated genes 
in patients clinically diagnosed with ATR-X syndrome. 
Our study shows the preponderance of differentially 
methylated genes within, or adjacent to, pericentro-
meric or telomeric chromosomal regions, suggesting a 
major role of heterochromatin in the pathophysiology 
of ATR-X, linked to the disruption of ATRX function in 
the context of its role as a regulator of heterochromatin 
dynamics.
Results
The epi‑signature identified in blood samples from ATR‑X 
patients
The genome-wide DNA methylation array of 20 blood 
samples obtained from ATR-X patients was compared 
with a reference cohort (controls). Various methylation 
changes at a single-probe level were identified across the 
genome, consisting of both hypo- and hypermethylation 
(estimate value  >  ±0.15) (Fig.  1a). Hierarchical cluster-
ing of significant probes (p < 0.01) clearly demonstrated 
a unique methylation profile and subclustering for these 
patients compared with our large laboratory reference 
cohort (Fig. 1c). The global methylation analysis revealed 
an increase in methylation at low methylation value 
regions (0.1–0.2 methylation value) in patients relative 
to controls (Fig. 1b). This pattern suggests that increased 
methylation is taking place in normally unmethylated 
regions, majority of which are normally located in pro-
moters and CpG islands.
Statistical filtering to identify regions with most robust 
methylation changes, using multiple parameters includ-
ing p value <0.01, F value >50, number of consecutive 
probes >4 and methylation difference  > ±20%, revealed 
16 genetic regions with significant statistical difference 
between ATR-X and controls (Table  1). Of these, 13 
regions showed hypermethylation (methylation differ-
ence higher than +0.2) and three regions showed hypo-
methylation (methylation difference lower than −0.2). 
These regions were distributed across the genome both 
outside (n = 5) and within CpG islands (n = 11), includ-
ing seven regions at gene promoter CpG islands and two 
intragenic CpG islands (Table 1). This epi-signature was 
specific to ATR-X patients and did not correlate with the 
type of mutation at the ATRX gene locus.
We then performed a single-patient analysis to identify 
possible patient-specific, as opposed to patient cohort-
specific, recurring methylation changes, using statistical 
parameters of p  <  0.01, methylation difference  > ±15%, 
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Fig. 1 a Volcano plot of methylation difference (estimate) between ATR-X and controls versus statistical significance (log p value) of individual 
probes. In red are highlighted probes with estimate value higher than 0.15. Positive estimate value = hypermethylation; negative estimate 
value = hypomethylation. b Histogram of all samples showing methylation value (X-axis) versus frequency of methylation levels across the genome 
(Y-axis) in ATR-X patients (red) and controls (blue). Patients with ATR-X showed a higher frequency of methylation at low methylation value regions 
(0.1–0.2 methylation value). Low methylation value regions are characteristic of promoter CpG islands. c Hierarchical clustering of probes dif-
ferentially methylated (p < 0.01) between ATR-X and controls demonstrating marked asymmetry of the two groups. Cases are represented in the 
columns and probes in the rows
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across four consecutive probes. First we observed that 
the cohort-specific epi-signature was absent in one of the 
patients (patient #12). A follow-up assessment showed 
that although this patient has previously been identified 
to carry a possible mutation in the ATRX gene, more 
recent data demonstrated that c.5579A>G; p.N1860S in 
the ATRX gene is indeed a benign polymorphism and 
hence this patent did not have the ATR-X syndrome. The 
remaining 17 patients with molecular diagnosis of ATR-
X, using the above statistical cutoffs, showed an average 
of 9.8 significant loci from the epi-signature per individ-
ual, with the minimum of four significant loci observed 
in two patients (#13 and #15). To evaluate the specific-
ity of this assay, we applied the ATR-X epi-signature in 
randomly selected 15 individuals, which included nor-
mal controls that were not part of the discovery cohort, 
as well as individuals with Fragile X syndrome, Prader–
Willi syndrome, Angelman syndrome and Beckwith–
Wiedemann syndrome. The majority of these individuals 
did not present any statistical significant changes at the 
ATRX epi-signature loci. Six control individuals showed 
significant changes at 1 or 2 ATRX epi-signature loci 
(POTEA and PACSIN1). These two genes had slightly 
higher level of variable DNA methylation and were as a 
result removed from the final ATRX epi-signature.
Biological interpretation
A more comprehensive gene list with methylation 
changes in the ATR-X group passing the following 
criteria, minimum of three consecutive probes with 
p < 0.01, F value across the region >50 and methylation 
difference > ±15% (i.e., at least a 15% methylation differ-
ence), showed an overrepresentation of genes involved 
in biosynthetic processes, nucleic acid metabolic pro-
cesses and methylation process (Table  2). Many of the 
genes are involved in transcriptional regulation: PRDM9 
encodes a histone H3 lysine-4 trimethyltransferase 
[23]; CTDP1 functions in recruiting RNA polymerase 
to DNA promoters and is an OMIM gene for congeni-
tal cataracts, facial dysmorphism and neuropathy [24]; 
TFB2M regulates mtDNA transcription and mainte-
nance [25]; also ZNF300, ZNF274 and ATF7IP2 are 
transcriptional regulators [26–28]. Another gene, QKI, 
regulates RNA splicing, export of target RNAs from the 
nucleus, translation of proteins and RNA stability [29]. 
In addition, three genes encode proteins associated with 
methylation process, including the histone H3 lysine-4 
trimethyltransferase, a known target of ATRX and the 
betaine–homocysteine methyltransferase 2-BHMT2, 
which catalyzes the methylation of homocysteine. Evi-
dences suggest that ATRX functions as a high-affinity 
RNA-binding protein and may regulate RNA stability 
of function [30]. These findings further support pre-
vious evidences, suggesting that ATRX has a role in 
regulating DNA and RNA metabolism and stability, 
as well as in the epigenetic regulation. Mutation at the 
ATRX gene may result in transcriptional deregulation 
of several genes across the genome and consequently 
Table 1 ATR-X methylation signature: significant regions detected by methylation array in ATR-X patients (n = 17) com-
pared with controls (n = 210)
Significant regions: Human reference genome Hg19. Probes >4, estimate (net methylation difference) > ± 20%, F value >50, p value <0.01. Gene promoters were 
defined as any sequence immediately surrounding the annotated 5ʹ end of the gene
Chr Region start Region stop # Probes Nearest gene Distance to gene 
(bp)
Within CpG 
island
Gene promoter/intragenic
chr1 228291476 228291715 5 C1orf35 453 No –
chr3 107810351 107810801 6 CD47 415 Yes –
chr3 109056339 109056907 4 DPPA4 0 No Promoter
chr4 124222 125122 5 ZNF718 0 Yes Intragenic/promoter
chr5 23506728 23507762 13 PRDM9 0 No promoter
chr5 134073420 134073589 5 CAMLG 581 No –
chr5 150284292 150284806 9 ZNF300 0 Yes Promoter
chr5 150325572 150326872 13 ZNF300P1 0 Yes Promoter
chr6 168045258 168045898 5 LOC401286 21624 No –
chr6 34498908 34499514 5 PACSIN1 0 Yes Intragenic
chr8 43131250 43132517 9 POTEA 15068 Yes –
chr10 38069509 38069955 4 ZNF248 0 Yes Intragenic
chr16 10479552 10480299 6 ATF7IP2 0 Yes Promoter
chr19 12305543 12306507 7 LOC100289333 0 Yes Promoter
chr20 623079 623431 4 SRXN1 3837 Yes –
chrY 21664286 21665031 4 BCORP1 0 Yes Promoter
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neurodevelopmental problems associated with the 
disorder.
Technical validation of the methylation array
To technically confirm the methylation array findings, 
we performed bisulfite mutagenesis/sequencing for two 
regions identified by the array: CD47 and ZNF300P1 
(Fig. 2; Additional file 1). The methylation array at these 
regions showed hypermethylation in ATR-X patients 
compared with controls (Fig. 2), with an average methyla-
tion value for the 6 CD47 probes of 0.55 and 0.8 in con-
trols and patients (1.45 fold increase), respectively, and 
average methylation for the 12 probes at ZNF300P1 of 
0.3 and 0.54 in controls and patients (1.8 fold increase), 
respectively. Using bisulfite mutagenesis/sequencing, 
we detected an overall increase in methylation at these 
regions in patients as compared to controls (Fig. 2). The 
bisulfite analysis showed average methylation at CD47 
gene of 0.19 and 0.31 in controls and patients (1.63 fold 
increase), respectively, and at ZNF300P1 gene of 0.16 and 
0.25 in controls and patients (1.56 fold increase), respec-
tively. These findings confirm the accuracy and specificity 
of the DNA methylation array data.
Uneven distribution of altered methylation sites across the 
genome
ATRX has multiple functions related to maintenance of 
heterochromatin and genomic integrity that are essential 
during mammalian development. Hence, we hypothe-
sized that genes in the ATRX epi-signature may be clus-
tered in highly heterochromatinized pericentromeric and 
telomeric regions of the chromosomes. Using a statisti-
cal cutoff of p < 0.01, estimate > ±0.15, F value >50 and 
probes >3, the top 40 genes were localized using Karyo-
gram view (Partek GS). We found that 17/40 (42.5%) of 
these genes in our signature mapped to telomeric and 
subtelomeric regions (defined as the last full cyto-band 
region on the chromosome) and 8/40 (20%) to pericen-
tromeric regions (defined as the full cyto-band region on 
the centromere of the chromosome), with the remain-
ing 15 (37.5%) scattered throughout the genome (Fig. 3). 
These findings suggest that ATRX dysfunction has a 
functional consequence to genes localized within hetero-
chromatinized regions of the genome, with potentially 
inappropriate gene expression of these genes/epi-signa-
ture secondary to loss of ATRX as a regulator of chroma-
tin integrity.
Discussion
The interplay between ATRX and DNA methylation has 
been evidenced by early studies in EBV-transformed cells 
from patients with ATR-X and controls, showing that 
mutations at the ATRX gene cause changes in the pat-
tern of methylation at subtelomeric and rDNA sequences 
[20]. Furthermore, loss of ATRX expression has been 
linked to extensive epigenomic alteration including CPG 
island hypermethylation observed in astrocytic tumors 
[31, 32]. The involvement of ATRX in the regulation of 
DNA methylation was further supported by the discovery 
that ATRX interacts with MeCP2 and cohesion subunits 
in the brain [33, 34]. MeCP2 is a methyl-CpG-binding 
domain protein with affinity for GC-rich sequences and 
methylated DNA which in turn facilitates the recruit-
ment of histone modifiers and chromatin remodeling 
complexes [35]. Similar to ATRX, MeCP2 is essential for 
neurodevelopment and mutations or duplications of the 
MeCP2 gene cause Rett syndrome, a neurodevelopmen-
tal disorder [36]. In addition, cohesin proteins play a role 
in the regulation of chromosome organization and gene 
expression by binding to unmethylated CTCF-associated 
regions and mutations at cohesin genes are associated 
with the developmental defects seen in patients with 
Cornelia de Lange syndrome [37]. MeCP2 was shown to 
recruit the helicase domain of ATRX to heterochromatic 
Table 2 Biological pathways identified by pathway analysis of the differentially methylated genes in ATR-X
Pathway analysis was performed with differentially methylated regions using cutoff of estimate > ±0.15, p < 0.01, F > 50 and probes >3
Biological pathway Biosynthetic process Nucleic acid metabolic process Methylation process
Number of genes in group 14 12 3
Fisher’s exact enrichment score −ln(p value) 5.9 4.6 4.6
Fisher’s exact right-tail p value <0.01 0.01 0.01
Genes DPPA4 PPAP2C ZNF274 ATF7IP2 PRDM9
ZNF718 ZNF486 CTDP1 ZNF486 BHMT2
PRDM9 ZNF274 TFB2M ZNF300 TFB2M
BHMT2 TFB2M QKI DPPA4
ZNF300 ATF7IP2 ZNF718 ZNF248
QKI CTDP1 UBE2U PRDM9
ZNF248 ALG10B
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regions in a DNA methylation-dependent manner [33]. 
In addition, MeCP2 has been reported to interact with 
DNA methyltransferase 1 in order to perform mainte-
nance methylation in vivo [38], as well as with histone H3 
lysine 9 methyltransferase enzymes, to reinforce a repres-
sive chromatin state by bridging DNA methylation and 
histone methylation [39].
Both ATRX protein and de novo DNA methyltrans-
ferases DNMT3A/B/L contain a histone-binding domain 
(ADD) that has been shown to play a role in the establish-
ment and maintenance of DNA methylation patterns. The 
ADD domain interacts with specific methylation modifi-
cations of histone lysine 4 and 9 (H3K4 and H3K9). The 
H3K4 methylation is associated with gene transcription 
and promoters DNA hypomethylation, whereas meth-
ylation of H3K9 is a heterochromatin-associated mark 
associated with transcriptional repression and DNA 
hypermethylation [16, 17]. H3K4 and H3K9 methylation 
is proposed to act as chromatin-based signals for regula-
tion of DNA methylation, while ATRX–heterochromatin 
interaction depends on these histone methylation mark-
ers [16]. ATRX ADD domain binds to the methylated 
H3K9 (H3K9me3) in conjunction with unmodified H3K4 
which are commonly seen in the repressed repeat ele-
ments. Therefore, mutations that functionally disrupt the 
ATRX protein and result in “mis-targeting” of ATRX–
heterochromatin interaction may provide a mechanism 
for abnormal DNA methylation patterns in patients with 
the ATR-X syndrome. While ATRX does not contain a 
DNA methyltransferase domain, we and others [20] have 
clearly shown association between ATRX mutation and 
abnormal patterns of DNA methylation.
The mechanism for ATRX induction of DNA methyla-
tion aberrations is not well known. Evidence has shown 
Fig. 2 Methylation visualization of significantly altered genes ZNF300P1 (a) and CD47 (b) in ATR-X patients (red) and controls (blue) identified by 
methylation array (top images) and bisulfite mutagenesis sequencing (bottom images). Top and bottom images show the same genomic coordinates. 
Methylation array figures were generated using Genomic Browser viewer (Partek) and shows methylation level 0 (not methylated) to 1 (100% meth-
ylated). CpG island and gene location and chromosome coordinates are also represented. The bottom image corresponds to methylation average 
based on bisulfite sequencing data from two ATR-X patients and two controls across the same regions from the top image. Bisulfite mutagenesis 
and sequencing analysis of these regions confirms effects seen by methylation array analysis
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an overlapping function of ATRX and ATF7IP2. A 
genome-wide promoter DNA methylation study, using 
methylation-dependent immunoprecipitation–Chip 
assay, has demonstrated hypermethylation at ATF7IP2 
gene in patients with ATRX mutation [40]. ATF7IP2, 
also known as MBD1-containing chromatin-associated 
factor 2, is known to bind to the transcription repres-
sion domain of the methylated cytosine-binding protein 
MBD1, as well as to interact with the H3K9 methyltrans-
ferase SETDB1 [28]. The overlapping protein interac-
tion of ATRX–ATF7IP2 suggests that they form part of 
the same repressive chromatin complex, which involves 
ATF7IP2-induced H3K9me3 and ATRX binding to 
H3K9me3. There is also evidence for ATF7IP2 and ATRX 
transcriptional activation role, through SP1 and DAXX 
interaction, in promyelocytic leukemia nuclear bodies 
[28, 41, 42]. These data suggest that ATRX and ATF7IP2 
have overlapping repressive/activating chromatin remod-
eling properties and potentially function in overlapping 
gene regulation pathways.
Most studies assessing the regulation of DNA methyla-
tion by ATRX have been focused on repetitive sequences 
and gene-specific methylation analysis. A recent study 
using methylation-sensitive restriction endonuclease has 
shown that ATRX mutations are associated with altera-
tions in the DNA methylation profiles in highly repetitive 
sequences [20]. Another study using bisulfite mutagene-
sis analysis in mice model has demonstrated that specific 
gene activation at ancestral pseudoautosomal regions, 
which are repetitive sequences regulated by ATRX, does 
not involve gene-specific changes on DNA methyla-
tion, but relies on the ATRX-dependent H3.3 deposition 
mechanism [43]. However, none of these studies have 
analyzed global DNA methylation and/or specific gene 
CpG islands methylation in non-repetitive sequences. By 
using a high-resolution methylation array technique and 
a large reference cohort (controls), our study has clearly 
shown the existence of a pattern of DNA methylation 
changes, including in promoter CpG islands, telomeric 
and pericentromeric regions, in patients with ATR-X. 
Fig. 3 Chromosomal localization of regions with significant methylation change in ATR-X patients using a less stringent cutoff of estimate > ±0.15, 
p < 0.01, F > 50 and probes >3. Figure shows location of significant methylation locus (horizontal line) at each chromosome. Pericentromeric and 
telomeric regions were defined as the last full cyto-band region on the chromosome
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Accordingly, in our study, most of the DNA methylation 
changes observed in patients with an ATRX gene muta-
tion were localized at telomeric and pericentromeric 
regions. How the epigenetic consequences of ATRX 
mutations actually result in the disease phenotype is 
not well understood. It is possible that the methylation 
alterations could result in differences in transcriptional 
regulation. For example, hypomethylation in a gene pro-
moter CpG island may result in increased transcription, 
whereas hypermethylation may result in decreased tran-
scriptional activity [6]. Gene pathway analysis showed 
that many of the genes identified in the ATR-X epi-sig-
nature are associated with DNA and RNA metabolic pro-
cess, which may be involved in the regulation of specific 
gene expression and corroborate to the cardinal develop-
mental processes disrupted in this rare disease; however, 
further research involving integrative analysis of gene 
expression and DNA methylation profiling to investi-
gate the relationship between these DNA methylation 
changes and gene expression is warranted.
Here, we propose that the most significant and recur-
rent regions altered in the genomic DNA of patients 
with ATR-X, consisting of 14 loci, provide an epige-
netic signature for this syndrome which may be used 
as a high sensitive and specific diagnostic biomarker to 
support the diagnosis of ATR-X, particularly in patients 
with phenotypical complexity and/or with ATRX gene 
sequence variants of unknown significance. Previous 
findings have demonstrated evidence of loss of DNA 
methylation in the repetitive elements [20]. While theo-
retically, it would be possible to use repetitive element 
methylation patterns as part of a unique ATRX muta-
tion epi-signature, routine analysis of the repetitive ele-
ments DNA methylation pattern can be challenging due 
to the lack of specificity for assays designed for assess-
ment of methylation of genomic repeats. Furthermore, 
most array or sequencing-based bisulfate protocols are 
limited to targeting unique genomic sequences. There-
fore, identification of a robust unique epigenetic signa-
ture across a large number of unique genetic sequences 
that we describe in this manuscript presents an oppor-
tunity for utilization of these findings in routine clinical 
diagnostics.
In addition to the ATR-X epi-signature described here, 
our group has recently demonstrated unique DNA meth-
ylation signatures in patients with two other conditions, 
including Floating–Harbor syndrome, which is caused by 
mutation in the SRCAP gene, as well as cerebellar ataxia, 
deafness and narcolepsy syndrome, which is caused by 
mutations in the DNMT1 gene [44, 45]. Other groups 
have also identified epi-signatures in patients with Sotos 
syndrome [46], and the X-linked intellectual disability 
caused by the KDM5C gene [47]. Taken together, these 
studies demonstrate the ability of genome-wide meth-
ylation array to accurately diagnose multiple epigenetic 
disorders. Utilization of this technology in routine clini-
cal practice will enable the discovery of new epigenetic 
biomarkers and will serve to enhance our understanding 
of human disease etiology. However, the identification 
of epigenetic variants of unknown clinical significance 
(E-VUS) will require delivery of testing to be performed 
in regulated clinical laboratories along with an adequate 
control cohort of normal samples, together with the 
development and implementation of clinical and labora-
tory testing guidelines, and availability and integration 
with pre- and posttest genetic counseling.
Conclusion
In conclusion, the observation of genome-wide epige-
netic defects in ATR-X patients expands our understand-
ing of the pathology of this disease, in which specific 
DNA methylation changes could lead directly to an aber-
rant expression of a number of genes in ATRX-deficient 
patients, particularly, but not restricted to telomeric and 
pericentromeric regions, thus contributing to the pheno-
types associated with ATR-X syndrome. In addition, the 
unique epi-signature identified for ATR-X syndrome can 
now be used as an epigenetic biomarker to support the 
diagnosis of new patients using a sensitive, specific and 
cost-effective GWMA testing protocol.
Methods
Sample collection, DNA extraction and genotyping
Peripheral blood samples from patients referred for 
genetic testing at the Greenwood Genetic Center were 
collected for methylation study. All patients were con-
sented and counseled for ATRX testing as part of their 
clinical referral. Ethical approval was consented by the 
Self Regional Healthcare Institutional Review Board (IRB 
#26). Genomic DNA was extracted from peripheral blood 
leukocyte using standard techniques. Patients presenting 
with the alpha thalassemia/mental retardation X-linked 
syndrome (ATR-X) underwent molecular diagnostic con-
firmation (ATRX gene analysis) and were selected for the 
methylation study. Table  3 shows the molecular (muta-
tions) characteristics of these patients. The ATR-X panel 
of patients is composed of 18 males with average age of 
12.2 years (ranging from 8 m to 27 years).
The methylation array of these patients was compared 
with a reference cohort composed of controls and indi-
viduals previously referred for microarray with no sig-
nificant methylation alteration. The reference cohort 
(controls) is composed of 210 male controls with average 
age of 7.3 years (2 m–53 years).
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Methylation array and data analysis
The DNA methylation array was performed using the 
Infinium HumanMethylation450 BeadChip (Illumina) 
according to standard protocol at the Genetic and 
Molecular Epidemiology Laboratory at McMaster Uni-
versity. The array coverage includes >485,000 individual 
methylation sites, 99% of RefSeq genes and 96% of CpG 
islands. Beta and intensity values for methylation were 
generated using the Illumina Genome Studio Software, 
and .idat files were imported to Partek Genomic Suite 
software (Partek GS). The patient cohort was compared 
with the laboratory reference cohort. Statistical analy-
sis was performed to compare ATR-X patients versus 
the control cohort using the ANOVA test to generate 
probe-level statistics, including p value (t test), F value 
(signal to noise) and estimate value (net methylation 
difference). The cutoff of estimate  >  ±0.20, p  <  0.01, 
F > 50 and probes >4 was used to select the top signifi-
cant regions to be included in the epi-signature. A less 
stringent cutoff of estimate > ±0.15, p < 0.01, F > 50 and 
probes > 3 was used for pathway analysis and karyogram 
view in order to include a larger number of regions in 
those analysis. Significant regions were mapped against 
the CpG islands and gene promoter regions. Genomic 
visualization of the data was performed using the karyo-
gram view toll (Partek GS) for chromosome distribution 
of differentially methylated regions, and the Genomic 
Browser Wizard (Partek GS) for locus-specific methyla-
tion levels.
Pathway analysis
The top 45 differentially methylated genes identified 
using a less stringent cutoffs (Additional file  2) were 
assessed using the pathway analysis tool in the Partek 
Genomics Suite software. Briefly, statistical analysis 
included Fisher’s exact test and was restricted to func-
tional groups at least two genes. Results show the enrich-
ment p value (p value of the Fisher exact test reflective of 
the number of the genes in versus not in the list or func-
tional group) and the enrichment score (negative log of 
the enrichment p value; a high score indicates that the 
genes in the functional group are overrepresented in the 
gene list).
Bisulfite mutagenesis
Genomic DNA isolated from blood of ATR-X patients 
(n = 2) and controls (n = 2) was sodium bisulfite treated 
using the EZ DNA Methylation-Direct Kit (Zymo 
Research) according to manufacturer’s instructions. DNA 
was amplified by nested PCR and the resulting products 
ligated into the pGEM-T Easy vector using a TOPO-TA 
cloning kit (Invitrogen). Positive clones were sequenced 
with Applied Biosystem 3730xl DNA Analyzer technol-
ogy (Center for Applied Genomics, McGill University). 
Clones were accepted at ≥95% conversion. Non-con-
verted cytosine residues and mismatched base pairs were 
used to ensure all clones originated from unique template 
DNA.
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Additional file 1: Figure S1. Methylation string diagrams of significantly 
altered regions in ATR-X patients and controls. Bisulfite mutagenesis and 
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Table 3 Clinical and  molecular characteristics of  ATR-X 
patients referred for methylation study
ATR‑X patient no. Mutation
1 c.109C>T; p.R37X
2 c.109C>T; p.R37X
3 c.109C>T; p.R37X
4 c.109C>T; p.R37X
5 c.109C>T; p.R37X
6 c.730A>C; p.I244L
7 c.758T>C; p.L253S
8 c.736T>C; p.R246C
9 c.736C>T; P.R246C
10 c.952G>T; p.G249C
11 c.4817G>A; p.S1606N
12 c.5579A>G; p.N1860S
13 c.5786A>G; p.K1929R
14 c.6254G>A; p.R2085H
15 c.6593A>G; p.H2198R
16 c.7156C>T; p.R2386X
17 c.7366_7367 InsA; p.M2456Nfs X42
18 Deletion of exon 2
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